Quantum Technology Partners

Magnolia Broadband, Inc. is a fabless semiconductor company based in Englewood, New Jersey, that specializes in wireless communications technology. Founded in 2000, the company has developed and patented Mobile Transmit Diversity (MTD), a beam-forming technology designed to enhance data throughput and coverage for wireless network operators without requiring modifications to existing infrastructure. MTD can be implemented as either a chip or a software solution, making it versatile for various applications. Magnolia boasts a robust intellectual property portfolio, including numerous issued and pending patents that underscore the fundamental and essential nature of its technology. The company’s innovations lead to a 40% increase in spectrum utilization, improved quality of service for voice and data, and enhanced battery life for devices. Magnolia's MTD technology supports multi-band standards and protocols, enabling rapid and cost-effective deployment in the wireless market.

Vaxart, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, specializing in the discovery and development of oral recombinant protein vaccines using its proprietary vaccine platform. The company is focused on creating oral vaccines that can generate broad and durable immune responses against various infectious diseases. Its product pipeline includes an oral tablet vaccine for norovirus, which has completed Phase I clinical trials, a seasonal influenza vaccine currently in Phase II trials, and vaccines targeting respiratory syncytial virus and coronavirus. Additionally, Vaxart is developing therapeutic vaccines for human papillomavirus-related conditions. The company aims to improve vaccination rates by offering a convenient, room temperature-stable tablet format, which is easier to distribute and administer compared to traditional injectable vaccines. Vaxart also has a research collaboration with Janssen Vaccines & Prevention B.V. to explore its oral vaccine platform for a universal influenza vaccine program.

BiPar Sciences Inc., based in Brisbane, California, is focused on developing PARP inhibitors as therapies for various cancers. The company's primary experimental product, BSI-201, is undergoing mid-stage trials for advanced breast cancer, ovarian cancer, and other tumors, particularly those that are therapy-resistant or difficult to treat. In addition to BSI-201, BiPar is working on a follow-on inhibitor candidate for pancreatic cancer and an iodothyronine program that possesses anti-tubulin properties, which could enhance the effectiveness of chemotherapy. BiPar has raised approximately $60 million in venture capital from several prominent investment firms and has also secured venture debt. In April 2009, the company announced its acquisition by a French pharmaceutical company for up to $500 million.

Vaxart, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, specializing in the discovery and development of oral recombinant protein vaccines using its proprietary vaccine platform. The company is focused on creating oral vaccines that can generate broad and durable immune responses against various infectious diseases. Its product pipeline includes an oral tablet vaccine for norovirus, which has completed Phase I clinical trials, a seasonal influenza vaccine currently in Phase II trials, and vaccines targeting respiratory syncytial virus and coronavirus. Additionally, Vaxart is developing therapeutic vaccines for human papillomavirus-related conditions. The company aims to improve vaccination rates by offering a convenient, room temperature-stable tablet format, which is easier to distribute and administer compared to traditional injectable vaccines. Vaxart also has a research collaboration with Janssen Vaccines & Prevention B.V. to explore its oral vaccine platform for a universal influenza vaccine program.

Corium International, Inc. is a biopharmaceutical company based in Menlo Park, California, that specializes in the development, manufacture, and commercialization of specialty pharmaceutical products utilizing transdermal and transmucosal delivery systems. The company offers a range of products, including the Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain management, and Crest Whitestrips for teeth whitening. Corium's pipeline includes Twirla, a hormonal contraceptive patch; MicroCor hPTH(1-34) for severe osteoporosis; and transdermal systems for Alzheimer's treatment, among others. Additionally, the company is advancing projects for psychiatric disorders and Parkinson's disease. Corium collaborates with several pharmaceutical companies, enhancing its research and development capabilities. The firm is recognized for its proprietary delivery technologies that improve therapeutic outcomes and safety profiles across various therapeutic areas.

StrataGent Life Sciences, Inc. is a specialty drug therapy company focused on creating painless and non-invasive alternatives to injectable therapies. The company's innovative products utilize proprietary microjet technology, which enables the delivery of both large and small therapeutic molecules without the need for devices to penetrate the skin. This approach aims to enhance patient comfort and compliance in medical treatments. StrataGent's commitment to advancing its technology was recognized in May 2004, when the company received a $2 million award from the Advanced Technology Program at the National Institute of Standards and Technology to further develop its microjet technology.

BiPar Sciences Inc., based in Brisbane, California, is focused on developing PARP inhibitors as therapies for various cancers. The company's primary experimental product, BSI-201, is undergoing mid-stage trials for advanced breast cancer, ovarian cancer, and other tumors, particularly those that are therapy-resistant or difficult to treat. In addition to BSI-201, BiPar is working on a follow-on inhibitor candidate for pancreatic cancer and an iodothyronine program that possesses anti-tubulin properties, which could enhance the effectiveness of chemotherapy. BiPar has raised approximately $60 million in venture capital from several prominent investment firms and has also secured venture debt. In April 2009, the company announced its acquisition by a French pharmaceutical company for up to $500 million.

IMI Intelligent Medical Implants develops and markets intelligent retinal implant systems for degenerative retinal disorders. The company offers The Intelligent Retinal Implant System, an adaptive visual prosthesis that bridges and replaces the defective information processing function of the real retina in patients with retinal degeneration. IMI Intelligent Medical Implants was founded in 2002 and is based in Zug, Switzerland.

Magnolia Broadband, Inc. is a fabless semiconductor company based in Englewood, New Jersey, that specializes in wireless communications technology. Founded in 2000, the company has developed and patented Mobile Transmit Diversity (MTD), a beam-forming technology designed to enhance data throughput and coverage for wireless network operators without requiring modifications to existing infrastructure. MTD can be implemented as either a chip or a software solution, making it versatile for various applications. Magnolia boasts a robust intellectual property portfolio, including numerous issued and pending patents that underscore the fundamental and essential nature of its technology. The company’s innovations lead to a 40% increase in spectrum utilization, improved quality of service for voice and data, and enhanced battery life for devices. Magnolia's MTD technology supports multi-band standards and protocols, enabling rapid and cost-effective deployment in the wireless market.

BiPar Sciences Inc., based in Brisbane, California, is focused on developing PARP inhibitors as therapies for various cancers. The company's primary experimental product, BSI-201, is undergoing mid-stage trials for advanced breast cancer, ovarian cancer, and other tumors, particularly those that are therapy-resistant or difficult to treat. In addition to BSI-201, BiPar is working on a follow-on inhibitor candidate for pancreatic cancer and an iodothyronine program that possesses anti-tubulin properties, which could enhance the effectiveness of chemotherapy. BiPar has raised approximately $60 million in venture capital from several prominent investment firms and has also secured venture debt. In April 2009, the company announced its acquisition by a French pharmaceutical company for up to $500 million.

Southampton Photonics Ltd., a U.K. startup. The company, with origins at Southampton University's Optical Research Center (ORC), aims to establish itself in the design and manufacture of fiber-optic components for the dense wave-division multiplexing (DWDM) and optical telecommunications market using technology from the university.

The company develops code division multiple access chipsets for wireless voice and data products.

Southampton Photonics Ltd., a U.K. startup. The company, with origins at Southampton University's Optical Research Center (ORC), aims to establish itself in the design and manufacture of fiber-optic components for the dense wave-division multiplexing (DWDM) and optical telecommunications market using technology from the university.